欢迎来到上海通蔚!

021-54845833/15800441009

品质保证 · 通蔚试剂

当前位置: 首页 > 科研产品 > 科研抗体 > 一抗 > 兔抗MAP3K4多克隆抗体
  • 兔抗MAP3K4多克隆抗体

    规格:
    数量:

    购买数量

    价格:
    • 品牌 : 通蔚生物
    • 目录号 : TW17106
    • 应用 : 仅供科研使用
    • 保存条件 : 低温保存
    • 货期 : 现货
    • 商品库存:80
  • 商品详情
  • 参考文献
  • 说明书下载
  • 商品评论0
  • 相关产品

中文名称:   兔抗MAP3K4多克隆抗体


英文名称:  Anti-MAP3K4 rabbit polyclonal antibody


别      名:   MTK1; MEKK4; MAPKKK4; PRO0412


相关类别  一抗


储      存:  冷冻(-20℃)


宿      主:  Rabbit


抗      原:  MAP3K4


反应种属: Human


标  记  物: Unconjugate

克隆类型:rabbit polyclonal


技术规格

Background:

The central core of each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of 3 protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which then activates a specific MAPK. While the ERK MAPKs are activated by mitogenic stimulation, the CSBP2 and JNK MAPKs are activated by environmental stresses such as osmotic shock, UV irradiation, wound stress, and inflammatory factors. This gene encodes a MAPKKK, the MEKK4 protein, also called MTK1. This protein contains a protein kinase catalytic domain at the C terminus. The N-terminal nonkinase domain may contain a regulatory domain. Expression of MEKK4 in mammalian cells activated the CSBP2 and JNK MAPK pathways, but not the ERK pathway. In vitro kinase studies indicated that recombinant MEKK4 can specifically phosphorylate and activate PRKMK6 and SERK1, MAPKKs that activate CSBP2 and JNK, respectively but cannot phosphorylate PRKMK1, an MAPKK that activates ERKs. MEKK4 is a major mediator of environmental stresses that activate the CSBP2 MAPK pathway, and a minor mediator of the JNK pathway. Two alternatively spliced transcripts encoding distinct isoforms have been described.

Applications:

ELISA, IHC

Name of antibody:

MAP3K4

Immunogen:

Synthetic peptide of human MAP3K4

Full name:

mitogen-activated protein kinase kinase kinase 4

Synonyms:

MTK1; MEKK4; MAPKKK4; PRO0412

SwissProt:

Q9Y6R4

ELISA Recommended dilution:

1000-5000

IHC positive control:

Human breast cancer and Human thyroid cancer

IHC Recommend dilution:

25-100